The end of the GSK project

The Imagelab collaboration with GlaxoSmithKline has now been completed, and our role as data collection center is finished.

Excerpts from the letter from GSK:

The last subject participating in the study completed examination on the 30th of May 2011. The overall safety profile of the compound remains favorable, no new microbleeds have been reported from any subjects on active treatment and no cases of vasogenic edema have been reported. [...] I hope that you agree with us, saying that it has been an interesting and challenging study for us all.

On behalf of the BA study team we would like to thank you all for your valuable support around the phase I program of our compound. We couldn’t have achieved this important milestone without your important engagement, and contribution. It has been a pleasure and privilege to work with you all.

All the best
For the BA study team

Pia Lisjö
Global Study Manager